QTEXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

QTREX Quantum Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 26, 2026

$1.40−0.10 (-6.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

QTREX Quantum Ltd. income statement

Annual QuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0.29	0	0	–	–	–	–
Cost of Revenue	0.29	0	0	–	–	–	–
Gross Profit	0.00	0	0	–	–	–	–
Research & Development	7.50	6.32	7.32	8.18	4.07	–	–
Selling, General & Admin	6.12	4.94	4.81	6.70	8.92	–	–
Selling & Marketing	0.59	0.75	0.75	1.33	1.98	–	–
General & Administrative	5.53	4.19	4.06	5.38	6.94	–	–
Total Costs & Expenses	–	–	0.55	–	–	–	–
Operating Income	-14	-11	-12	-15	-13	6.27	1.27
Interest Expense	–	–	1.16	–	–	–	–
Other Non-Operating Income	0.34	0.04	0.53	-0.28	-4.23	–	–
Asset Impairment Charges	–	–	–	–	1.27	–	–
Pretax Income	-13	-11	-11	-15	-17	7.23	4.58
Income Tax Expense	0	0	0	–	–	–	–
Income from Continuing Operations	–	–	–	10	17	7.23	4.58
Net Income incl. Noncontrolling Interests	–	–	-11	-15	-17	-7.23	-4.58
Net Income	-13	-11	-11	-15	-17	17	–
EPS (Basic)(per share)	-0.45	-0.60	-0.93	-1.39	-3.24	-3.67	-2.40
EPS (Diluted)(per share)	-0.45	-0.60	-0.93	-1.39	-3.24	-3.67	-2.40
Shares Outstanding (Basic, Weighted)(shares)	30	19	12	11	5.31	1.97	1.90
Shares Outstanding (Diluted, Weighted)(shares)	30	19	12	11	5.31	1.97	1.90
EBITDA	–	–	–	-15	-13	–	–
Non-Interest Expense	–	–	0.72	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 0.7%
Operating margin: -4713.8%
Net margin: -4574.4%
Return on equity, FY2025: -397.9%

Financial strength

Current ratio: 2.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –